TuHURA Biosciences Inc

HURA

Company Profile

  • Business description

    TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

  • Contact

    10500 University Center Drive
    Suite 110
    TampaFL33612
    USA

    T: +1 813 875-6600

    https://www.tuhurabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    19

Stocks News & Analysis

stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,979.4022.00-0.24%
CAC 407,831.4918.94-0.24%
DAX 4024,337.9297.100.40%
Dow JONES (US)45,010.29507.851.14%
FTSE 1009,144.1882.690.91%
HKSE25,667.18129.110.51%
NASDAQ21,020.02127.330.61%
Nikkei 22541,826.34655.021.59%
NZX 50 Index12,805.1311.070.09%
S&P 5006,358.9149.290.78%
S&P/ASX 2008,709.4027.80-0.32%
SSE Composite Index3,605.7323.430.65%

Market Movers